Febrile Illness Outbreak Investigation in Sundarharicha-5, Foklan Tapu, Morang District

Nepal Health Research Council (NHRC)
Ramshahpath, Kathmandu
March 2018
Outbreak Investigation team

Name Designation and Office

Prof. Dr. Anjani Kumar Jha Executive Chairman, NHRC
Mr. Ashok Pandey Research Officer, NHRC
Mr. Arun Kumar Sah Research Officer, NHRC
Mr. Uday Kumar Yadhav Laboratory Technologist, NPHL
Dr. Jay Shankar Chaudhary Medical Officer, KZH, Brt
Mr. Lalit Narayan Chaudhary Laboratory Technologist, KZH, Brt

Overall Concept Development to Report writing team

Mr. Arun Kumar Sah
Mr. Ashok Pandey
Mr. Pradeep Belbase
Prof. Dr. Anjani Kumar Jha

Data entry support

Ms. Kopila Khadka
Ms. Nirmala Prajapati

Data analysis support

Mr. Achyut Raj Pandey
Mr. Bihungam Bista
Mr. Namra Kumar Mahato
Dr. Amita Pradhan
Dr. Meghnath Dhimal

Recommended Citation: Sah AK, Pandey A, Belbase P, Jha AK. Febrile illness outbreak Investigation in Sundarharicha-5 Foklan Tapu, Morang District Kathmandu, Nepal: Nepal Health Research Council, 2018
ACKNOWLEDGEMENT

I would like to offer my sincere thanks to my research team who contributed from the conception to completion of this study. I am also thankful to the Epidemiology and Diseases Control Division (EDCD) and National Public Health Laboratory (NPHL) for their cooperation to conduct this study. My special thanks go to Dr. Roshan Pokhrel, the Medical Superintendent of Koshi Zonal Hospital for the inputs; Mr. Raj Kumar Mahato, Director of NPHL for this study and Dr. Jay Chaudhary for his support during data collection. I am grateful to Koshi Zonal Hospital, Nobel Medical College and Teaching Hospital for providing data of ill patient. I would like to particularly thank to WHO Biratnagar office who provided the early information about outbreak.

I am also thankful to administrative and financial coordination efforts made by Mr. Nirbhay Kumar Sharma and Mr. Subodh Kumar Karna of NHRC. At the last but not the least, we are very thankful to all health post, zonal hospital, health staffs and referral hospitals of Morang who support for this study.

Prof. Dr. Anjani Kumar Jha
Executive Chairman
Nepal Health Research Council
TABLE OF CONTENTS

Acknowledgement ........................................................................................................ II
Table of Contents ........................................................................................................... III
List of Tables .................................................................................................................. IV
List of abbreviation ....................................................................................................... V
Executive summary ....................................................................................................... VI
Background .................................................................................................................... 1
About the Febrile illness ............................................................................................... 1
Justification of febrile illness (outbreak investigation) process ..................................... 1
About febrile illness and Leptospirosis ....................................................................... 1
Objectives ....................................................................................................................... 3
Case definition ............................................................................................................... 3
Methodology .................................................................................................................... 4
Study Design ................................................................................................................... 4
Study Area ....................................................................................................................... 4
Investigation Site ............................................................................................................. 4
Sample Size and Sample Population .......................................................................... 4
Data Collection Tools and Techniques ...................................................................... 4
Process of data collection and screening camp ......................................................... 5
Data management and analysis .................................................................................. 5
Process for doing the Laboratory Analysis ............................................................... 6
Ethical considerations .................................................................................................. 6
Findings ........................................................................................................................... 7
Leptospirosis (rapid) test done by NPHL ................................................................. 7
Influenza test from throat swab .................................................................................. 7
Rapid testing of Leptospirosis ..................................................................................... 7
Socio-demographic characteristics of participants .................................................. 7
Exposure to Respiratory Illness .................................................................................. 8
Animal Exposure .......................................................................................................... 8
Leptospirosis case ......................................................................................................... 10
List of Tables

Table 1: Socio-demographic characteristics .................................................................7
Table 2: Exposures to respiratory illness .......................................................................8
Table 3: Animal Exposures (within past 8 weeks) ........................................................8
Table 4: Medications/Biological exposure of participants .............................................9
Table 5: Exposure in public gathering .......................................................................10
Table 6: Laboratory Diagnosis of Leptospirosis ...........................................................10
Table 7: Association of Symptoms with IgM ...............................................................10
Table 8: Lab findings of Leptospirosis according to different variables ......................12
# LIST OF ABBREVIATION

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPHO</td>
<td>District Public Health Officer</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>EDCD</td>
<td>Epidemiology and Disease Control Division</td>
</tr>
<tr>
<td>BPKIHS</td>
<td>BP Koirala Institute of Health Science</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-Linked Immunosorbent Assay</td>
</tr>
<tr>
<td>KZH</td>
<td>Koshi Zonal Hospital</td>
</tr>
<tr>
<td>NHRC</td>
<td>Nepal Health Research Council</td>
</tr>
<tr>
<td>ILI</td>
<td>Influenza like Illness</td>
</tr>
<tr>
<td>VA</td>
<td>Verbal Autopsy</td>
</tr>
<tr>
<td>KII</td>
<td>Key Informant Interview</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY

On the date of 24 July 2017, the major national daily newspapers reported that there were two death cases from unknown disease were found in the Morang district, Sundarharicha Municipality 5, Foklan Tapu. According to news, the death cases were the 14-year-old male child and 5-year-old female child. The common symptom of the disease was fever, coryza, headache, drowsiness.

Addressing the outbreak, a descriptive study was conducted with the team of experts in affected area to investigate and identify the etiological and epidemiological causes, how this happens in the outbreak area for the period of July 2017 to December 2017. Verbal Autopsy (VA) and Key in-depth guidelines were used to identify the major causes of febrile illness. Verbal autopsy interview and Key in-depth interview was done and once the diagnosis was confirmed the patient (134 patients, 37 household) was sent for the further full treatment also. The leptospirosis to a human being is contracted through the contaminated urine of infected domestic and wild animals. The disease is common in summer and rainy season. Socioeconomic factors, environmental conditions, and geographical areas are the associated with the risk factors of Leptospirosis. Leptospirosis is a widespread water-borne spirochetal zoonotic disease caused by leptospires.

The analysis was done in SPSS Statistics 20 version. Descriptive and inferential statistics was done to determine the association of major risk factors to the disease occurrence. Qualitative data (VA and KII) was analyzed manually. Ethical approval was obtained from ethical review board at the NHRC (Reg. no. 382/2017) on expedited process according to the outbreak investigation provision of national ethical guidelines.

Findings suggested that out of 83 blood samples 5 were antibody G and antibody M positive for leptospira, 20% were exposed to respiratory illness and three participants below 9 years have fA (H1N1) Pdm09. Study suggested that large portion i.e. 49% were IgM positive, 375 were IgM negative where as 13% stayed equivocal. Total of 87% of participants were found exposed to domestic animals including pets, 20% exposed to insects bites, 15% with closed exposure with swine and 2.4% exposed to animal necropsy. Participants were found 8.4% with receiving regular immunization vaccine, 1.2% received influenza vaccine and 1.2% were on medications.

Research hence concluded that not just exposure to ill contributed to the risk of developing illness but also increases the risk of infection. Also, Leptospira was responsible agent for the manifestation of an outbreak. Raising awareness of disease patterns and epidemiology of incidence may enrich practices of prevention of leptospirosis. This research finding could be used by concerned stakeholders in emergency and outbreak response to manage risk factors at outbreak sites. This finding may be used for further to assessing the capacity of outbreak response teams, to provide an evidence-based for planning and allocating outbreak management and public health resources and the overall disease burden of leptospirosis.
About the Febrile illness

On the date of 24 July 2017, the major national daily newspaper reported that there were two death cases from unknown disease were found in the Morang district, Sundarharicha Municipality 5, Foklan Tapu. According to news, the death cases were the 14-year-old male child and 5-year-old female child. The common symptom of the disease was fever, coryza, headache, drowsiness.

In the phone call, District Public Health Officer (DPHO) Morang district, said besides administering treatment to the sick people, the medical team was also conducting sample collection and awareness programme from 25 July 2017. The information provided by the Health Administrator of the Epidemiology and Disease Control Division (EDCD) said with the collaboration of WHO and BPKIHS, screening program is going on. A team consisting of a medical officer, public health researcher, and laboratory technologist was mobilized to Foklan Tapu for the outbreak study.

The purpose of the febrile illness outbreak investigation is to identify the aetiological and epidemiological causes, how this happens in the outbreak area. It also involves implementing control measures to prevent additional illness and evaluating the impact of those control measures to make sure that the problem has been adequately addressed.

Justification of febrile illness outbreak investigation process

Epidemiology and disease control division (EDCD) was collected the 7 serum sample from Sundarharicha, ward no. 5, Foklan Tapu, Morang at NPHL for analysis of on 2074/04/12. Three different tests like Leptospirosis (rapid), Scrub Typhus (ELISA) and Dengue (rapid) test was done. In Scrub typhus and Dengue laboratory test, the result was negative. Among the 7 serum sample for Leptospirosis, 2 samples was found to be IgM Reactive. (For detail annex 4)

About febrile illness and Leptospirosis

The infectious sources of febrile illness remain poorly consider in many parts of the world in this century. This is due to lack of human resources, medical facilities, and limited diagnostic facilities. In Nepal, febrile illness is one of the main reasons for seeking medical attention in rural areas, but there is limited information on the incidence of specific infections.

Leptospirosis has been reported as an emerging zoonosis and the widespread zoonotic disease in the world(1). Leptospirosis is presumed to be the widespread zoonosis in the Asia (2). The leptospirosis to a human being is contracted through the contaminated urine of infected domestic and wild animals(1). The disease is common in summer and rainy season(3). Socioeconomic factors, environmental conditions, and geographical areas are the associated with the risk factors of Leptospirosis(4).Leptospirosis is a widespread water-borne spirochetal zoonosis disease caused by leptospires.
In the Asian region, leptospirosis is largely a water-borne disease. Till date, the frequency, incidence, and prevalence of Leptospirosis have not been well demonstrated in Nepal. Leptospirosis is known to be endemic and sometimes epidemic in India as well as demonstrated in Bangladesh also, which occurred commonly in the urban and rural poor population (6,7). Nepal being in similar tropical and geographical region, the country has also verified Leptospirosis infection occasionally. Only, few studies have been carried out in this regard and there was only few evidence of Leptospirosis in the country (6,8,9). This study has been demonstrated evidence of Leptospirosis infection as one of the etiology of unknown febrile illnesses of Foklan Tapu of Morang district Nepal.
OBJECTIVES

- To establish existence and magnitude of the outbreak
- To identify the possible source and mode of transmission
- To detect the possible causes/risk factors/vehicles of transmission and
- To make recommendations to implement preventive and control measures

Case definition

Clinical case definition of unknown disease

Those people who were suffering from Fever, Corzya, Headache and Drowsiness from last 30 days.

Laboratory diagnosis

Blood, urine and sputum sample (Was follow the standard guidelines)

Case classifications:

Clinically confirmed: A case that meets the clinical case definition

Laboratory-confirmed: A case that meets the clinical case definition by laboratory procedures
METHODOLOGY

Study Design
A descriptive study was conducted Sundar Haraicha Munacipility ward no 5, Foklan Tapu of Morang District. In this study all the people were included from the particular pocket area and were screened for the febrile illness and after screening. Once the diagnosis was confirmed the patient was sent for the further full treatment also.

Study Area
The study population was people residing in the Sundar Haraicha Munacipility ward no 5, Foklan Tapu of Morang District. Those people who have met the above case definition were selected. The investigation period was from July 2017 to December 2018.

Investigation Site
In the 37 households, only 160 populations were residing in the Sundar Haraicha Munacipility ward no 5, Foklan Tapu of Morang District. In the screening and data collection time, we got only 134 people.

Sample Size and Sample Population
A total number of 134 people who were suffering from Fever, Corzya, Headache and Drowsiness from last 30 days were checked by medical doctor during the field visit. Among them, 86 blood sample and 37 sputum samples were taken from the patients for the laboratory analysis. The blood and sputum sample were collected and brought to the National Public Health Laboratory, Kathmandu, for further microbiological analysis.

Two verbal autopsies were done among the household heads of decease family. Five Key in-depth interviews were taken from local community leader, local health service providers, Medical officer of Koshi Zonal Hospital, District public health officer and Medical director of WHO.

Data Collection Tools and Techniques
For quantitative data, semi-structured questionnaire was used to collect information from the screened population. Similarly, laboratory transportation form taken from NPHL was used for sample collection and appropriate transportation as well as to remove the duplication. Interview was done before collecting the sample.

Verbal Autopsy (VA) and Key in-depth guidelines were also used to identify the major causes of febrile illness. Verbal autopsy interview and Key in-depth interview was done.
Process of data collection and screening camp

The team includes Medical officer (Koshi Zonal Hospital (KZH)), Medical Lab Technologist (KZH and NPHL), Research team (NHRC), upon arrival to Sundar Haricha, reviewed the VDC and health facility data. The secondary information like total number of household, affected population and their distribution, geographical variations, ongoing services, etc. Together with local health workers, Female Community Health Volunteers (FCHVs), newly elected local leaders developed a field work plan.

The team organized health camps covering most affected areas of Foklan Tapu for 5 days. Assessment of febrile illness (Leptospirosis illness, Influenza like Illness (ILI)) cases was done using the standard case definition along with line listing of other patients. An index case was discovered.

Collection of Blood Specimen:

Whole blood was collected for leptospirosis examination. Serum was separated from blood by using the serological techniques. Blood sample was collected for immediate provisional and detail laboratory diagnosis. In order to separate serum from blood, drawn blood was stored at room temperature for least 30 minutes for complete clot formation. Serum was separated from the clotted blood by centrifugation to prevent hemolysis. After centrifugation was complete, serum (supernatant) was decanted using sterile technique into plastic freezing vials. Serum was stored at 4 °C for short term and at -20 °C for long time periods. Serum was transported at 0 °C to 4 °C to the NPHL. Based on this findings of NPHL (annex 4), we made our concept for doing the laboratory analysis for Leptospirosis by rapid methods and ELISA. All the process was maintained by Medical lab technician of NPHL.Rapid testing for provisional diagnosis was done on the spot to identify the positive cases.

Specimen Collection and Transportation of Throat Swab

For influenza suspected people sputum sample was collected. Specimen was collected from the throat Infections people. A plain cotton swab was collected as much exudates as possible from tonsils, posterior pharyngeal wall and other area that is inflamed or bears exudates. After collecting the throat swab, it was immediately placed into a sterile tube for transport to NPHL.

Data management and analysis

Quantitative data was collected and cleaned as well as checked for consistency and entered in the MS excel. The analysis was done in SPSS Statistics 20 version. Descriptive and inferential statistics was done to determine the association of major risk factors to the disease occurrence. Qualitative data (VA and KII) was analyzed manually.
Process for doing the Laboratory Analysis

Epidemiology and disease control division (EDCD) was collected the 7 serum sample from Sundarharicha, ward no. 5, Foklan Tapu, Morang at NPHL for analysis of on 2074/04/12. Three different tests like Leptospirosis (rapid), Scrub Typhus (ELISA) and Dengue (rapid) test were done. In Scrub typhus and Dengue laboratory test, the result was negative. Among the 7 serum sample for Leptospirosis, 2 samples were found to be IgM Reactive.

Ethical considerations

Ethical approval was obtained from ethical review board at the NHRC (Reg. no. 382/2017) on expedited process according to the outbreak investigation guidelines. Written consent was taken from all the participants after informing about the study and clarifying their role in the study.
Leptospirosis (rapid) test done by NPHL

Epidemiology and disease control division (EDCD) collected the 7-serum sample from Sundarharicha, ward no. 5, Foklan Tapu, Morang NPHL on 2074/04/12. Three different tests like Leptospirosis (rapid), Scrub Typhus (ELISA) and Dengue (rapid) test were done. In Scrub typhus and Dengue laboratory test, the test result was negative. Among the 7 serum sample, for Leptospirosis 2 sample was found to be IgM Reactive.

Influenza test from throat swab

37 throat swabs was collected from the febrile disease outbreak area of Foklan Tapu. Influenza test was done at the NPHL by applying the influenza PCR test. The result of Influenza test shows that 3 participants have fA (H1N1) pdm09 positive case. These all participants were below 9 years.

Rapid testing of Leptospirosis

83 blood samples were collected and sent to NPHL for necessary laboratory diagnosis. Rapid testing was done in the field to identify the positive cases. Findings show that there were 5 (Five) antibody G and antibody M positive cases for leptospira.

Socio-demographic characteristics of participants

The participants were suffering from fever, coryza, headache, and drowsiness like symptoms onset dates ranged from July 20-July 30, 2017. Among the total 83 cases, the median respondent’s age was 18 years (range = 1 year–85 years). The median age among the cases was 17 years (range = 1 year 52 years). The majority (65%) of the participants were female. According to caste/group grouping of Nepal, the majority (84%) of the participants were disadvantage janajati followed by (16%) upper caste groups. Similarly, on the religion, Hindu participants were slightly higher (92%) than the census report 2011, which accounts 81.3% of country’s population. (Table 1)

<table>
<thead>
<tr>
<th>Characteristics(n=83)</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>29</td>
<td>34.9</td>
</tr>
<tr>
<td>Female</td>
<td>54</td>
<td>65.1</td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disadvantaged janajatis</td>
<td>70</td>
<td>84.3</td>
</tr>
<tr>
<td>Upper caste groups</td>
<td>13</td>
<td>15.7</td>
</tr>
<tr>
<td><strong>Religion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hindu</td>
<td>76</td>
<td>91.6</td>
</tr>
</tbody>
</table>
Exposure to Respiratory Illness

Two out of ten (20%) of the participants were exposed with respiratory illness people. Among the exposed participants, majority (69%) of them were contacted with household/intimate people. The data available suggest that exposure to ill either through exposure to partner or during induced family member, increases the risk of developing illness. In addition, the longer the duration of exposure the higher the risk of infection for febrile illness.

Table 2: Exposures to respiratory illness

<table>
<thead>
<tr>
<th>Exposures to respiratory illness</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact respiratory illness (n=83)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>16</td>
<td>19.3</td>
</tr>
<tr>
<td>No</td>
<td>67</td>
<td>80.7</td>
</tr>
<tr>
<td>Types of contact (n=16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Household/ Intimate</td>
<td>11</td>
<td>68.8</td>
</tr>
<tr>
<td>Institutional setting</td>
<td>5</td>
<td>31.2</td>
</tr>
</tbody>
</table>

“An isolated island, Inadequate sanitation, open defecation, open riversides in all directions, the very low distance of pet shelter and people bedroom with low awareness is prevalent in Foklan Tapu. We keep in touch with the febrile disease outbreak time”. – KII, DPHO Morang

Animal Exposure

For the Leptospirosis, there is always a risk of contagion for people who have contact with infected soil/water or animals where the Leptospira bacteria are present. Generally, people who work animals or outdoors may be at increased risk for contagion and infection.

Table 3: Animal Exposures (within past 8 weeks)

<table>
<thead>
<tr>
<th>Animal exposure (n=83)</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animals living in his/her home (including pets)</td>
<td>72</td>
<td>86.7</td>
</tr>
<tr>
<td>Animal bite (including wild and domestic animals)</td>
<td>4</td>
<td>4.8</td>
</tr>
<tr>
<td>Insect bite (e.g. mosquito, tick, and spider)</td>
<td>16</td>
<td>19.3</td>
</tr>
<tr>
<td>Close contact with rodents (e.g. rats, mice, squirrels, prairie dogs)</td>
<td>16</td>
<td>19.3</td>
</tr>
<tr>
<td>Close contact with rodent droppings or rodent nests</td>
<td>8</td>
<td>9.6</td>
</tr>
<tr>
<td>Close contact with birds (includes turkeys and chickens)</td>
<td>16</td>
<td>19.3</td>
</tr>
<tr>
<td>Close contact with bird droppings</td>
<td>11</td>
<td>13.3</td>
</tr>
</tbody>
</table>
Out of total participant, a majority (87%) of the participant was exposed to an animal living in his/her home (including pets). One out of five (20%) of the participants were exposed with insect bite (e.g. mosquito, tick, and spider) likewise, close contact with rodents (e.g. rats, mice, squirrels, prairie dogs), and close contact with birds (includes turkeys and chickens). Around (15%) of the participants were close contact with swine and so on. Very few (2.4%) of the participants were exposed to performing or assisting with an animal necropsy and hunting or fishing.

“Most of the people are poor and living unhygienically. In every household, there are a lot of pet animals like a pig, buffalo, goat, duck, and chicken. Their pets entered in their kitchen and rooms easily. Their pet house and their bedroom are nearby”. – KII, Local Health Workers

“Like the darkness under the candle” Foklan Tapu is nearby with the well facilitated Itahari and Biratnagar cities. Many people in the Foklan Tapu have not managed the waste properly. They eat unhealthy food, and meat. Their home has no proper sanitation. They use open space mostly river for defecation”. – KII, FCHV

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Close contact with swine</td>
<td>12</td>
<td>14.5</td>
</tr>
<tr>
<td>Hunting or fishing</td>
<td>2</td>
<td>2.4</td>
</tr>
<tr>
<td>Skin, dress, or eating wild game</td>
<td>3</td>
<td>3.6</td>
</tr>
<tr>
<td>Spending time on a farm, rural area or petting zoo</td>
<td>4</td>
<td>4.8</td>
</tr>
<tr>
<td>Performing or assisting with an animal necropsy</td>
<td>2</td>
<td>2.4</td>
</tr>
</tbody>
</table>

Table 4: Medications/Biological exposure of participants

<table>
<thead>
<tr>
<th>Characteristics (n=83)</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
<td>Percent</td>
</tr>
<tr>
<td>Receiving any immunizations</td>
<td>7</td>
<td>8.4</td>
</tr>
<tr>
<td>Receiving an influenza vaccine in last one month</td>
<td>1</td>
<td>1.2</td>
</tr>
<tr>
<td>Taking any medications including prescription, over the counter, or herbal remedies</td>
<td>1</td>
<td>1.2</td>
</tr>
</tbody>
</table>

After the febrile disease outbreak, only (8.4%) of the participants were receiving the immunization. Only 1.2% of the participants were receiving an influenza vaccine in the last one month. Likewise, only 1.2% of the participants were taking any medications including prescription, over the counter, or herbal remedies.

“Poor people were neglects the minor symptoms. In this febrile disease outbreak cases, most of the villagers were affected with the same symptoms. The team of health post moves to the place of incident. We started the screening camp among the ill people and given medicine for symptomatic treatment”. – KII, Local health
Table 5: Exposure in public gathering

<table>
<thead>
<tr>
<th>Exposure (n=83)</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Working with any chemicals or toxins</td>
<td>2</td>
<td>81</td>
</tr>
<tr>
<td>Frequency</td>
<td>Percent</td>
<td>Frequency</td>
</tr>
<tr>
<td>Attending any gathering, Mela (community program) in last 1 month</td>
<td>7</td>
<td>76</td>
</tr>
<tr>
<td>Frequency</td>
<td>Percent</td>
<td>Frequency</td>
</tr>
<tr>
<td>Attending any party, function in last 1 month</td>
<td>10</td>
<td>74</td>
</tr>
<tr>
<td>Frequency</td>
<td>Percent</td>
<td>Frequency</td>
</tr>
</tbody>
</table>

On the exposure of participants, around 11% of the participants were attended the party, function within 1 month. 8.4% of the participants were attended any gathering, Mela (community program) within the last 1 month.

“Local political leader who won in the local election was gathered the local community for winning party (BHOJ). Every one of the village was invited and ate chicken and pulau”.-A Local people, Foklan Tapu

Leptospirosis case

Table 6: Laboratory Diagnosis of Leptospirosis

<table>
<thead>
<tr>
<th>Laboratory Diagnosis (n=83)</th>
<th>Leptospira immunoglobulin M (IgM)</th>
<th>Leptospira immunoglobulin G (IgG)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
<td>Percent</td>
<td>Frequency</td>
<td>Percent</td>
</tr>
<tr>
<td>Positive</td>
<td>41</td>
<td>49.4</td>
<td>21</td>
<td>25.3</td>
</tr>
<tr>
<td>Negative</td>
<td>31</td>
<td>37.3</td>
<td>51</td>
<td>61.4</td>
</tr>
<tr>
<td>Equivocal</td>
<td>11</td>
<td>13.3</td>
<td>11</td>
<td>13.3</td>
</tr>
</tbody>
</table>

IgM positive antibodies to Leptospira species detected suggesting recent infection. Almost half (49%) of the participants were IgM positive antibodies to Leptospira species followed by 37% negative IgM and Only 13% equivocal. IgG positive antibodies to Leptospira species detected suggesting the prolonged time of time. One out of 4 (25%) participants was IgM positive antibodies to Leptospira species followed by (61%) negative and 13% equivocal.

Table 7: Association of Symptoms with IgM

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Positive</th>
<th>Negative</th>
<th>Equivocal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
<td>Percent</td>
<td>Frequency</td>
</tr>
<tr>
<td>Fever</td>
<td>11</td>
<td>13.3</td>
<td>6</td>
</tr>
<tr>
<td>Sweats</td>
<td>5</td>
<td>6.0</td>
<td>0</td>
</tr>
<tr>
<td>Chills rigors</td>
<td>1</td>
<td>1.2</td>
<td>0</td>
</tr>
<tr>
<td>Cough</td>
<td>12</td>
<td>14.5</td>
<td>7</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>4</td>
<td>4.8</td>
<td>6</td>
</tr>
<tr>
<td>Symptom</td>
<td>Count</td>
<td>Percent</td>
<td>Count</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------</td>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td>Chest pain</td>
<td>7.2</td>
<td>5</td>
<td>6.0</td>
</tr>
<tr>
<td>Runny nose</td>
<td>3</td>
<td>3.6</td>
<td>4</td>
</tr>
<tr>
<td>Sore throat</td>
<td>4</td>
<td>4.8</td>
<td>7</td>
</tr>
<tr>
<td>Difficulty swallowing</td>
<td>2</td>
<td>2.4</td>
<td>6</td>
</tr>
<tr>
<td>Ear pain</td>
<td>0</td>
<td>0.0</td>
<td>1</td>
</tr>
<tr>
<td>Redeyes</td>
<td>2</td>
<td>2.4</td>
<td>2</td>
</tr>
<tr>
<td>Sore throat</td>
<td>0</td>
<td>0.0</td>
<td>5</td>
</tr>
<tr>
<td>Joint pain</td>
<td>3</td>
<td>3.7</td>
<td>2</td>
</tr>
<tr>
<td>Enlarged gland</td>
<td>2</td>
<td>2.4</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td>2.4</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2</td>
<td>2.4</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>0.0</td>
<td>2</td>
</tr>
<tr>
<td>Dark bloody urine</td>
<td>1</td>
<td>1.2</td>
<td>0</td>
</tr>
</tbody>
</table>

Among the Leptospira (IgM) positive participants on the different symptoms shown by the participants. Among cough symptoms shown participants, (15%) of them were IgM positive followed by (8%) IgM negative and nearly (4%) equivocal. Similarly, around (13%) of the IgM positive participants were shown the fever followed by 6% sweats, (5%) a sore throat and shortness of breath and so on.
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Response</th>
<th>No Leptospirosis</th>
<th>Leptospirosis</th>
<th>Total</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Frequency</td>
<td>Percent</td>
<td>Frequency</td>
<td>Percent</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>12</td>
<td>36.4</td>
<td>17</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>21</td>
<td>63.6</td>
<td>33</td>
<td>66</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Disadvantaged Janjati</td>
<td>25</td>
<td>75.8</td>
<td>45</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>Upper caste groups</td>
<td>8</td>
<td>24.2</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>Religion</td>
<td>Hindu</td>
<td>31</td>
<td>93.9</td>
<td>45</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>Buddhist</td>
<td>2</td>
<td>6.1</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Christian</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Animals pets</td>
<td>No</td>
<td>4</td>
<td>12.1</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>29</td>
<td>87.9</td>
<td>43</td>
<td>86</td>
</tr>
<tr>
<td>Animal bite</td>
<td>No</td>
<td>33</td>
<td>100</td>
<td>46</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Insect bite</td>
<td>No</td>
<td>29</td>
<td>87.9</td>
<td>38</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>4</td>
<td>12.1</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Contact with rodents</td>
<td>No</td>
<td>29</td>
<td>87.9</td>
<td>37</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>3</td>
<td>9.1</td>
<td>13</td>
<td>26</td>
</tr>
<tr>
<td>Contact with rodent droppings</td>
<td>No</td>
<td>30</td>
<td>93.8</td>
<td>43</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1</td>
<td>3.1</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>Contact with birds</td>
<td>No</td>
<td>29</td>
<td>87.9</td>
<td>37</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>3</td>
<td>9.1</td>
<td>13</td>
<td>26</td>
</tr>
<tr>
<td>Contact with bird droppings</td>
<td>No</td>
<td>31</td>
<td>93.9</td>
<td>40</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1</td>
<td>3</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>Contact with swine</td>
<td>No</td>
<td>31</td>
<td>93.9</td>
<td>40</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>2</td>
<td>6.1</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>Hunting and fishing</td>
<td>No</td>
<td>32</td>
<td>97</td>
<td>49</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Use skin dress or eat wild</td>
<td>No</td>
<td>32</td>
<td>97</td>
<td>48</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>
Qualitative

Verbal Autopsy (14 years child)

According to the participant, her son died of unknown febrile illness. The deceased was 14 years old male. The deceased was exposed to a contaminated water source while swimming. He ate the flesh meat taken from the hilly region of Shankhusawa district. The flesh meat of buffalo was rotten. They have never taken the precaution for freezing the meat. He had a cough with sputum from last 3 days. It was associated with muscle pain, muscle cramps, particularly affecting the muscles in the lower back and calves. Deceased was taken to the BPKIHS, Dharan hospital and admitted there for a week. After the medical testing, the doctor told to the deceased family for taking the cerebrospinal fluid (CSF). Hospital doctor gives him usual treatment in the intensive care unit (ICU). They never allowed visiting the patient during the ICU time. Suddenly, on the 8th day of ICU, when I was inside the ICU of the hospital. He sat down and asked for water meanwhile he dead on the spot.

Verbal Autopsy (4 years child)

According to the participant, her daughter died of unknown febrile illness. The deceased was 4-years-old female. She had the fever for five days. The deceased had been attended the party organized by a newly elected local leader. The party was for celebrating the winning happiness of local election. Where she ate chicken and pulao (Fried rice). When the fever was very high, her mother gave her medicine, which she had bought from a nearby pharmacy. After taking medicine, she felt better and got back to normal life. At the same night, a buffalo died, after bitten by a dog (sick dog as told by villager) and they just cooked the dead buffalo which everybody ate. In the third day of meat eating date, she suddenly had a high fever in the morning with muscle cramps. She was barely able to open her eyelid. The family members took her to a nearby hospital in Itahari, but in the middle of the day, she died.
CONCLUSION

Nepal remains a place for the frequent outbreak of febrile illness and the sometimes leptospirosis outbreaks go without identifying the causative agents. Based on the evidence from clinical and laboratory findings, the leptospirosis outbreak was recorded in Foklan Tapu, Sundarharicha Municiaplity of of Morang district. Leptospira was responsible agent for the manifestation of an outbreak.

Awareness rising of disease patterns and epidemiology of incidence may enrich practices of prevention of leptospirosis. This research finding could be used by concerned stakeholders in emergency and outbreak response to manage risk factors at outbreak sites. This finding may be used for further to assessing the capacity of outbreak response teams, to provide an evidence-based for planning and allocating outbreak management and public health resources and the overall disease burden of leptospirosis.


**Annex 1: Work Schedule**

<table>
<thead>
<tr>
<th>SN</th>
<th>Tasks to be performed</th>
<th>Personnel assigned for task</th>
<th>No. of person days required</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Proposed blood, urine and sputum sample collection, providing standard guidelines for test and providing test report</td>
<td>Lab Technician</td>
<td>1*7=10</td>
<td>Per day 30 sample was collected including cold chain maintain and transportation</td>
</tr>
<tr>
<td>2</td>
<td>Preparation of data collection guidelines, clinical examination, screening, interpretation of laboratory test result</td>
<td>Medical doctor (Clinician)</td>
<td>1*7=10</td>
<td>Per day 30 people was checked</td>
</tr>
<tr>
<td>3</td>
<td>Concept paper preparation, Preparation of data collection guidelines, Coordination and data collection</td>
<td>Researcher</td>
<td>2*7=10</td>
<td>Coordination, management and data collection</td>
</tr>
</tbody>
</table>
Annex 2: Some pictures from outbreak investigation site

- Preparation for data collection
- Clinical investigation
- Doctor check up
- Blood sample collection
- Data Collection
- Verbal Autopsy
Developing Screening camp and data collection area

Developing Blood and throat swab sample collection area

Data collection area and people gathering

Deceased children
Annex 3: Press Release

प्रेस विज्ञापन

२०७४ साल, २३
मोर्ग जिल्लाको सुन्दर हर्वा, फोक्लान टापुमा ५, फोक्लान टापुमा फैलिएको अञ्चल रोगको अध्ययन र अनुसन्धान।

विभिन्न सन्चार माध्यममा प्रकाशित समाचारमा मोर्ग जिल्लाको सुन्दर हर्वा, फोक्लान टापुमा ५, फोक्लान टापुमा फैलिएको अञ्चल रोगको कारण २ जना वालवालाको मृत्यु भएको खबर आएर संगी नेपाल स्वास्थ्य अनुसन्धान परिषद् (स्वास्थ्य मन्त्रालय) को गम्भीर आवागमणि भएको छ। उक्त महामारीको कारण पता लगाउनको लागि नेपाल स्वास्थ्य अनुसन्धान परिषदले सम्बंधित नियमावली (EDCD, NPHL, DPHO Morang, Koshi Regional Hospital) संग समन्वय गरी यहाँबाट अनुसन्धान टोली पठाएको थियो।

उक्त अनुसन्धान टोलीले जितला जन- स्वास्थ्य कार्यालय मोर्ग, कॉर्पोरेट क्षेत्र अस्पताल, नोबेल मेडिकल कलेज, विश्व स्वास्थ्य संगठन विराटनगर कार्यालय, सुन्दर हर्वा स्वास्थ्य चौकी र सम्बंधित वहा अन्तर्गतका वहा कार्यालय र राजनीतिक कमीहरुको समन्वय र सहयोगमा महामारी स्थलमा गई स्वास्थ्य परिणाम, रगतको नमूना संकलन, महामारीको अध्ययन, स्वतन्त्रता अध्ययन र निरीक्षण तथा मृत्यु भएका वालवालाको घरमा गई मौकिक जानकारी संकलन गरेको थियो।

प्राथमिक अध्ययन अनुसार महामारी स्थलका मानसिकहरमा ३८ डिग्री भन्दा माध्यम ज्योरो आउने, रिग्रो लाग्ने, टाउको दुल्लुको कारणहरूलाई आधारानुसार स्वास्थ्य परिणाम र Rapid Test बाट रगतको नमूना जाँच गर्न Leptospira नामक विश्व स्वास्थ्य फोक्लान टापुमा फैलिएको स्थलले महामारीको वर्तमान र अन्तर्गतका तथा वालवालाको नमूना र तत्परता पत्रकारण २ जनामा Leptospirosis Positive रेखिएको जानकारी संगमेट NPHL माफिक प्राप्त भएको थियो।

उक्त अनुसन्धान टोलीले फोक्लान टापुमा दुल्लुका सम्पूर्ण मात्रामा नमूना संकलन गरी अन्य विशेष जाँचको लागि NPHL पाठिएको र उक्त परिणामको निर्णय आएवा पत्रकारण यस महामारीका बारेमा यस जानकारी प्रविधिदेवन माफिक सामाजिकको सारणी गरिएको छ।

उक्त रोग सर-सफाईको कमी, घर पाण्ड जनावरको संगाको अंतिम निकाट सम्बन्ध, मरेका र डड्पालेका मासू खायाउन फैलिएको हुन सक्छ। भौगोलिक विवरण, जंगलले अन्यतर नौकरबन्द, स्वास्थ्य परिणामको लागि खोला तर्च आउन पर्ने वायाना, गर्मी, निकाशता र जन चेतनाको कमीका कारणले महामारी फैलिएको र २ जना बालवालाको संमूह गुमाउन पर्ने रेखिएको छ। उक्त महामारीपत्र पाठिएको भित्ति यस्ता महामारी जन-२०७४ घटनाहरू दोहोरिन निर्णय आयान्दित पर्ने जन चेतना, सर-सफाई र तथा महामारी रोगहरुको बारेमा विस्तृत जानकारी सम्मूल नागरिकहरमा पुस्तकाले पर्ने टहकारी आवश्यकता रेखिएको छ।


प्र. डा. अनन्ती कुमार भा

कार्यकारी अध्यक्ष
### Annex 4: National Public Health Laboratory Report

<table>
<thead>
<tr>
<th>S.No</th>
<th>Name of the patient</th>
<th>Leptospira (Rapid)</th>
<th>Scrub Typhus (ELISA)</th>
<th>Hemagglutination (Rapid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Nita Rai</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
<tr>
<td>2</td>
<td>Prabhat Rai</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
<tr>
<td>3</td>
<td>Pasang Tamang</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
<tr>
<td>4</td>
<td>Bikesh Tamang</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
<tr>
<td>5</td>
<td>Aakai Tamang</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
<tr>
<td>6</td>
<td>Anil Rai</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
<tr>
<td>7</td>
<td>Everest Rai</td>
<td>IgG+ IgM- Non reactive</td>
<td>Negative</td>
<td>NS1 antigen Negative</td>
</tr>
</tbody>
</table>

Approved by

Dr. Raj Kumar Malhotra
Director
NPHL
Annex 5: ELISA for Leptospira IgM
Annex 6: ELISA for IgG

Leptospira IgM

ELISA

Only for in-vitro diagnostic use

Product Number: LEPM0660 (96 Determinations)
ENGLISH

1. INTRODUCTION

Leptospirosis (also known as Weil's syndrome) is probably the most widespread zoonosis in the world. It is caused by infection with spirochete bacteria of the genus Leptospira and affects humans as well as a broad spectrum of animal hosts. The incidence is significantly higher in warm climate countries than in temperate regions. The disease is seasonal, with peak incidence occurring in summer or fall in temperate regions, where temperature is the limiting factor in survival of leptospires, and during rainy seasons in warm climate regions, where rapid desiccation would otherwise prevent survival.

Natural reservoirs for the pathogenic Leptospira interrogans include rodents as well as a large variety of domesticated mammals (e.g., pigs, cattle, and dogs). Leptospires occupy the lumen of nephritic tubules in their natural host and are shed into the urine.

Transmission can occur when humans are directly or indirectly exposed to the urine of infected animals or a urine-polluted environment. Leptospires gain entry into the human blood stream via cuts, skin abrasions or mucous membranes through contact with moist soil, vegetation, and contaminated waters; handling infected animal tissues; and ingestion of food and water. Leptospires are rarely transmitted from human to human.

The incubation period is usually 5-14 days, with a range of 2-30 days. The spectrum of clinical symptoms is extremely wide. The vast majority of leptospiral infections are either subclinical or result in very mild illness and recover without any complications. Clinical manifestations of leptospirosis range from mild influenza-like symptoms to severe life-threatening disease forms, characterized by jaundice, renal failure, bleeding and severe pulmonary hemorrhage.

The clinical presentation of leptospirosis is biphasic, with the acute or septicaemic phase lasting about a week, followed by the immune phase, characterized by antibody production and excretion of leptospires in the urine. Most of the complications of leptospirosis are associated with localization of leptospires within the tissues during the immune phase and thus occur during the second week of the illness. The classical syndrome of Weil’s disease represents only the most severe presentation. It is characterized by jaundice, renal failure, hemorrhage and myocarditis with anuriae.

<table>
<thead>
<tr>
<th>Species</th>
<th>Disease</th>
<th>Symptoms</th>
<th>Mechanism of Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptospira spp.</td>
<td>Leptospirosis</td>
<td>Wide spectrum of clinical symptoms; mild influenza-like symptoms to severe life-threatening disease forms</td>
<td>direct or indirect contact with the urine of an infected animal (via cuts, skin abrasions or mucous membranes)</td>
</tr>
<tr>
<td></td>
<td>Weil's disease</td>
<td>jaundice, renal failure, haemorrhage and myocarditis with anuriae</td>
<td></td>
</tr>
</tbody>
</table>

The presence of pathogen resp. infection may be identified by:

- **Pathogen detection**: dark-field microscopy, culture from blood, urine, cerebrospinal fluid or tissues
- **PCR**
- **Serology**: microscopic agglutination test (MAT), ELISA

2. INTENDED USE

The Leptospira IgM-ELISA is intended for the qualitative determination of IgM class antibodies against Leptospira spp. in human serum or plasma (heparin).

3. PRINCIPLE OF THE ASSAY

The qualitative immunoenzymatic determination of IgM-class antibodies against Leptospira spp. is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microtiter strip wells are coated with Leptospira antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgM conjugate is added. This conjugate binds to the captured Leptospira-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product.

The intensity of this product is proportional to the amount of Leptospira-specific IgM antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

4. MATERIALS

4.1. Reagents supplied

- **Leptospira Coated Wells (IgM)**: 12 break-apart 8-well snap-off strips coated with Leptospira antigens; in resealable aluminium foil.
- **IgM Sample Diluent**: 1 bottle containing 100 ml of phosphate buffer (10 mM) for sample dilution; pH 7.2 ± 0.2; anti-human IgG, coloured green, ready to use; white cap; < 0.1% MIT; < 0.1% CMI; < 0.1% NaNo.
- **Stop Solution**: 1 bottle containing 15 ml sulphuric acid, 0.2 mol/l, ready to use; red cap.
- **Washing Solution (20x conc.)**: 1 bottle containing 50 ml of a 20-fold concentrated phosphate buffer (0.2 M), pH 7.2 ± 0.2, for washing the wells; white cap; < 1% Ethanol, < 0.5% Bromonitrooxaline.
- **Leptospira anti-IgM Conjugate**: 1 bottle containing 20 ml of peroxidase labelled antibody to human IgM in phosphate buffer (10 mM); coloured red, ready to use; black cap; < 1% Ethanol, < 0.5% Bromonitrooxaline.
Febrile Illness Outbreak Investigation in Sundarharicha-5 Foklan Tapu, Morang District

- **TMB Substrate Solution**: 1 bottle containing 15 ml 3,3',5,5'-tetramethylbenzidine (TMB), < 0.04%; ready to use; yellow cap; < 0.0001% CMIT; < 0.0001% MIT; < 0.01% H2O2.
- **Leptospira IgM Positive Control**: 1 vial containing 2 ml control (human serum or plasma), coloured yellow; ready to use; red cap; < 0.1% Bromotetradecanil, < 0.1% MIT.
- **Leptospira IgM Cut-off Control**: 1 vial containing 3 ml control (human serum or plasma), coloured yellow; ready to use; green cap; < 0.1% Bromotetradecanil, < 0.1% MIT.
- **Leptospira IgM Negative Control**: 1 vial containing 2 ml control (human serum or plasma), coloured yellow; ready to use; blue cap; < 0.1% MIT; < 0.1% CMIT; < 0.1% NaN3.

**4.2. Materials supplied**
- 1 Strip holder
- 1 Cover foil
- 1 Test protocol
- 1 Distribution and identification plan

**4.3. Materials and Equipment needed**
- ELISA microwell plate reader, equipped for the measurement of absorbance at 450/620 nm
- Incubator 37°C
- Manual or automatic equipment for rinsing wells
- Pipettes to deliver volumes between 10 and 1000 µl
- Vortex tube mixer
- Deionised or (freshly) distilled water
- Disposable tubes

**5. STABILITY AND STORAGE**

Store the kit at 2...8°C. The opened reagents are stable up to the expiry date stated on the label when stored at 2...8°C.

**6. REAGENT PREPARATION**

It is very important to bring all reagents, samples and standards/controls to room temperature (20...25°C) before starting the test run.

**6.1. Coated snap-off strips**
The ready to use break-apart snap-off strips are coated with Leptospira antigen. Immediately after removal of the strips, the remaining strips should be resealed in the aluminum foil along with the desiccant supplied and stored at 2...8°C.

**6.2. Washing Solution (20x conc.)**
Diute Washing Solution 1 + 19, e.g. 10 ml Washing Solution + 190 ml fresh and germ free redistilled water. The diluted buffer is stable for 5 days at room temperature. Crystals in the concentrate disappear by warming up to 37°C in a water bath.

**6.3. TMB Substrate Solution**
The reagent is ready to use and has to be stored at 2...8°C, away from the light. The solution should be colourless or could have a slight blue tinge. If the substrate turns into blue, it may have become contaminated and should be thrown away.

**6.4. IgM Sample Diluent**
The solution contains anti-human IgG class antibodies to eliminate competitive inhibition from specific IgG class antibodies and to remove rheumatoid factor.

**7. SPECIMEN COLLECTION AND PREPARATION**

Use human serum or plasma (heparin) samples with this assay. If the assay is performed within 5 days after sample collection, the specimens should be kept at 2...8°C; otherwise they should be aliquoted and stored deep-frozen (-70...-20°C). If samples are stored frozen, mix thawed samples well before testing. Avoid repeated freezing and thawing. Heat inactivation of samples is not recommended.

**7.1. Sample Dilution**
Before assaying, all samples should be diluted 1:100 with IgM Sample Diluent. Dispense 10 µl sample and 1 ml IgM Sample Diluent into tubes to obtain a 1:100 dilution and thoroughly mix with a Vortex.

**8. ASSAY PROCEDURE**

**8.1. Test Preparation**
Please read the test protocol carefully before performing the assay. Result reliability depends on strict adherence to the test protocol as described. If performing the test on ELISA automatic systems we recommend increasing the washing steps from three to five and the volume of Washing Solution from 300 pl to 350 pl to avoid washing effects. Pay attention to chapter 12. Prior to commencing the assay, the distribution and identification plan for all specimens and standards/controls should be carefully established on the result sheet supplied in the kit. Select the required number of microtitre strips or wells and insert them into the holder.
24 Febrile Illness Outbreak Investigation in Sundarharicha-5 Foklan Tapu, Morang District

Please allocate at least:

1 well (e.g. A1) for the Substrate Blank.
1 well (e.g. B1) for the Negative Control.
2 wells (e.g. C1 + D1) for the Cut-off Control and
1 well (e.g. E1) for the Positive Control.

It is recommended to determine standards/controls and patient samples in duplicate.
Perform all assay steps in the order given and without any appreciable delays between the steps.
A clean, disposable tip should be used for dispensing each standard/control and sample.

Adjust the incubator to 37 ± 1 °C.

1. Dispense 100 µl standards/controls and diluted samples into their respective wells. Leave well A1 for the Substrate Blank.
2. Cover wells with the foil supplied in the kit.
3. Incubate for 1 hour ± 5 min at 37 ± 1 °C.
4. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well three times with 300 µl of Washing Solution. Avoid overflows from the reaction wells. The soak time between each wash cycle should be > 5 sec. At the end carefully remove remaining fluid by tapping strps on tissue paper prior to the next step!
   Note: Washing is critical! Insufficient washing results in poor precision and falsely elevated absorbance values.
5. Dispense 100 µl Leptospira anti-IgM Conjugate into all wells except for the Substrate Blank well (e.g. A1). Cover with foil.
6. Incubate for 30 min at room temperature. Do not expose to direct sunlight.
7. Repeat step 4.
8. Dispense 100 µl TMB Substrate Solution into all wells.
9. Incubate for exactly 15 min at room temperature (20...25 °C) in the dark.
10. Dispense 100 µl Stop Solution into all wells in the same order and at the same rate as for the TMB Substrate.
    Any blue color developed during the incubation turns into yellow.
11. Measure the absorbance of the specimen at 450/620 nm within 30 min after addition of the Stop Solution.

8.2. Measurement

Adjust the ELISA Microwell Plate Reader to zero using the Substrate Blank in well A1.

If - due to technical reasons - the ELISA reader cannot be adjusted to zero using the Substrate Blank in well A1, subtract the absorbance value of well A1 from all other absorbance values measured in order to obtain reliable results!

Measure the absorbance of all wells at 450 nm and record the absorbance values for each standard/control and patient sample in the distribution and identification plan.

Dual wavelength reading using 620 nm as reference wavelength is recommended.
Where applicable calculate the mean absorbance values of all duplicates.

9. RESULTS

9.1. Run Validation Criteria
In order for an assay to be considered valid, the following criteria must be met:

- **Substrate Blank** in A1: Absorbance value < 0.100
- **Negative Control** in B1: Absorbance value < 0.200 and < Cut-off
- **Cut-off Control** in C1 and D1: Absorbance value 0.150 – 1.300
- **Positive Control** in E1: Absorbance value > Cut-off

If these criteria are not met, the test is not valid and must be repeated.

9.2. Calculation of Results
The Cut-off is the mean absorbance value of the Cut-off Control determinations.

Example: Absorbance value Cut-off Control 0.44 + absorbance value Cut-off control 0.42 = 0.86 / 2 = 0.43

Cut-off = 0.43

9.2.1. Results in Units [NTU]

Patient (mean) absorbance value x 10 = [NovaTec Units = NTU]

Example: 1.591 x 10 = 37 NTU (Units) / 0.43
9.3. Interpretation of Results

<table>
<thead>
<tr>
<th>Cut-off</th>
<th>10 NTU</th>
<th>&lt; 10 NTU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>&gt; 11 NTU</td>
<td>Antibodies against the pathogen are present. There has been a contact with the antigen (pathogen resp. vaccine).</td>
</tr>
<tr>
<td>Equivocal</td>
<td>9 – 11 NTU</td>
<td>Antibodies against the pathogen could not be detected clearly. It is recommended to repeat the test with a fresh sample in 2 to 4 weeks. If the result is equivocal again the sample is judged as negative.</td>
</tr>
<tr>
<td>Negative</td>
<td>&lt; 9 NTU</td>
<td>The sample contains no antibodies against the pathogen. A previous contact with the antigen (pathogen resp. vaccine) is unlikely.</td>
</tr>
</tbody>
</table>

Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data. In immunocompromised patients and newborns serological data only have restricted value.

10. SPECIFIC PERFORMANCE CHARACTERISTICS

10.1. Precision

<table>
<thead>
<tr>
<th>Intraassay</th>
<th>n</th>
<th>Mean (OD)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample #1</td>
<td>23</td>
<td>0.478</td>
<td>1.9</td>
</tr>
<tr>
<td>Sample #2</td>
<td>24</td>
<td>0.893</td>
<td>1.8</td>
</tr>
<tr>
<td>Sample #3</td>
<td>24</td>
<td>0.448</td>
<td>1.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interassay</th>
<th>n</th>
<th>Mean (NTU)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample #1</td>
<td>12</td>
<td>19.15</td>
<td>3.2</td>
</tr>
<tr>
<td>Sample #2</td>
<td>12</td>
<td>10.10</td>
<td>4.2</td>
</tr>
</tbody>
</table>

10.2. Diagnostic Specificity

The diagnostic specificity is defined as the probability of the assay of scoring negative in the absence of the specific analyte. It is 96.0 %.

10.3. Diagnostic Sensitivity

The diagnostic sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is > 98 %.

10.4. Interferences

Interferences with hemolytic, lipemic or icteric specimen are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.5 mg/ml bilirubin.

10.5. Cross Reactivity

It cannot be excluded that Cytomegalovirus, Treponema pallidum and Coxiella specimens may result in false-positive IgM antibody results. In addition, it should be noted that IgM class antibodies directed against Leptospira generally remain detectable for months or even years but at low titer.

Note: The results refer to the groups of samples investigated; these are not guaranteed specifications.

11. LIMITATIONS OF THE PROCEDURE

Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values.

12. PRECAUTIONS AND WARNINGS

- In compliance with article 1 paragraph 2b European directive 98/79/EC the use of the in vitro diagnostic medical devices is intended by the manufacturer to secure suitability, performances and safety of the product. Therefore the test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The use of the testkits with analyzers and similar equipment has to be validated. Any change in design, composition and test procedure as well as for any use in combination with other products not approved by the manufacturer is not authorized; the user himself is responsible for such changes. The manufacturer is not liable for false results and incidents for these reasons. The manufacturer is not liable for any results by visual analysis of the patient samples.
- Only for in-vitro diagnostic use.
- All materials should be regarded and handled as potentially infectious.
- All components of human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive.
- Do not interchange reagents or strips of different production lots.
- No reagents of other manufacturers should be used along with reagents of this test kit.
- Do not use reagents after expiry date stated on the label.
- Use only clean pipette tips, dispensers, and lab ware.
- Do not interchange screw caps of reagent vials to avoid cross-contamination.
Annex 6: ELISA for IgG

NovaLisa®

Leptospira IgG

ELISA

Only for in-vitro diagnostic use

Product Number: LEPG0660 (96 Determinations)
ENGLISH

1. INTRODUCTION

Leptospirosis (also known as Weil's syndrome) is probably the most widespread zoonosis in the world. It is caused by infection with spirochete bacteria of the genus Leptospira and affects humans as well as a broad spectrum of animal hosts. The incidence is significantly higher in warm climate countries than in temperate regions. The disease is seasonal, with peak incidence occurring in summer or fall in temperate regions, where temperature is the limiting factor in survival of leptospires, and during rainy seasons in warm climate regions, where rapid desiccation would otherwise prevent survival.

Natural reservoirs for the pathogenic Leptospira interrogans include rodents as well as a large variety of domesticated mammals (e.g. pigs, cattle and dogs). Leptospires occupy the lumen of nephritic tubules in their natural host and are shed into the urine.

Transmission can occur when humans are directly or indirectly exposed to the urine of infected animals or a urine-polluted environment. Leptospires gain entry into the human blood stream via cuts, skin abrasions or mucous membranes through contact with moist soil, vegetation, and contaminated waters; handling infected animal tissues; and ingestion of food and water.

Leptospires are rarely transmitted from human to human.

The incubation period is usually 5-14 days, with a range of 2-30 days.

The spectrum of clinical symptoms is extremely wide. The vast majority of leptospiral infections are either subclinical or result in very mild illness and recover without any complications. Clinical manifestations of leptospirosis range from mild influenza-like symptoms to severe life-threatening disease forms, characterized by jaundice, renal failure, bleeding and severe pulmonary hemorrhage.

The clinical presentation of leptospirosis is bilateral, with the acute or septicular phase lasting about a week, followed by the immune phase, characterized by antibody production and excretion of leptospires in the urine. Most of the complications of leptospirosis are associated with localization of leptospires within the tissues during the immune phase and thus occur during the second week of the illness. The classical syndrome of Weil's disease represents only one of the most severe presentation. It is characterized by jaundice, renal failure, hemorrhage and mycarditis with arrhythmias.

<table>
<thead>
<tr>
<th>Species</th>
<th>Disease</th>
<th>Symptoms</th>
<th>Mechanism of Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptospira spp.</td>
<td>Leptospirosis</td>
<td>Wide spectrum of clinical symptoms: mild influenza-like symptoms to severe life-threatening disease forms</td>
<td>direct or indirect contact with the urine of an infected animal (via cuts; skin abrasions or mucous membranes)</td>
</tr>
<tr>
<td></td>
<td>Weil's disease</td>
<td>jaundice, renal failure, haemorrhage and mycarditis with arrhythmias</td>
<td></td>
</tr>
</tbody>
</table>

The presence of pathogen resp. infection may be identified by:
- Pathogen detection: dark-field microscopy
  - culture from blood, urine, cerebrospinal fluid or tissues
  - PCR
- Serology: microscopic agglutination test (MAT), ELISA

2. INTENDED USE

The Leptospira IgG-ELISA is intended for the qualitative determination of IgG class antibodies against Leptospira spp. in human serum or plasma (heparin).

3. PRINCIPLE OF THE ASSAY

The qualitative immunoenzymatic determination of IgG-class antibodies against Leptospira spp. is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microwell strip wells are coated with Leptospira antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgG conjugate is added. This conjugate binds to the captured Legionella-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product.

The intensity of this product is proportional to the amount of Legionella-specific IgG antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

4. MATERIALS

4.1. Reagents supplied
- Leptospira Coated Wells (IgG): 12 break-apart 8-well snap-off strips coated with Leptospira antigens, in resealable aluminum foil.
- IgG Sample Diluent: 1 bottle containing 150 ml of phosphate buffer (10 mM) for sample dilution; pH 7.2 ± 0.2; coloured yellow; ready to use; white cap; < 0.1% MTT; < 0.1% CMT; < 0.1% NaN3.
- Stop Solution: 1 bottle containing 15 ml sulphuric acid, 0.2 mol/l; ready to use; red cap.
- Washing Solution (20x conc.): 1 bottle containing 50 ml of a 20-fold concentrated phosphate buffer (0.2 M), pH 7.2 ± 0.2; for washing the wells; white cap; < 1% ethanol; < 0.5% Bromontdioxane.
- Leptospira anti-IgG Conjugate: 1 bottle containing 20 ml of peroxidase labelled antibody to human IgG in phosphate buffer (10 mM); coloured blue; ready to use; black cap; < 1% ethanol; < 0.5% Bromontdioxane.
TMB Substrate Solution: 1 bottle containing 15 ml 3,3',5,5'-tetramethylbenzidine (TMB), <0.04 %; ready to use; yellow cap; <0.0001 % CNIT; <0.0001 % MIT; <0.01 % H2O2.

Leptospira IgG Positive Control: 1 vial containing 2 ml control (human serum or plasma); coloured yellow; ready to use; red cap; <0.1 % Bromonitrosooxan; <0.1 % MIT.

Leptospira IgG Cut-off Control: 1 vial containing 3 ml control (human serum or plasma); coloured yellow; ready to use; green cap; <0.1 % Bromonitrosooxan; <0.1 % MIT.

Leptospira IgG Negative Control: 1 vial containing 2 ml control (human serum or plasma); coloured yellow; ready to use; blue cap; <0.1 % MIT; <0.1 % CNIT; <0.1 % NaNS.

4.2. Materials supplied
- 1 Strip holder
- 1 Cover foil
- 1 Test protocol
- 1 Distribution and identification plan

4.3. Materials and Equipment needed
- ELISA microwell plate reader, equipped for the measurement of absorbance at 450/620 nm
- Incubator 37 °C
- Manual or automatic equipment for rinsing wells
- Pipettes to deliver volumes between 10 and 1000 μl
- Vortex tube mixer
- Deionised or (freshly) distilled water
- Disposable tubes

5. STABILITY AND STORAGE
Store the kit at 2±8 °C. The opened reagents are stable up to the expiry date stated on the label when stored at 2±8 °C.

6. REAGENT PREPARATION
It is very important to bring all reagents, samples and standards/controls to room temperature (20±25 °C) before starting the test run!

6.1. Coated snap-off strips
The ready to use break-apart snap-off strips are coated with Leptospira antigen. Immediately after removal of the strips, the remaining strips should be resealed in the aluminium foil along with the desiccant supplied and stored at 2±8 °C.

6.2. Washing Solution (20x conc.)
Dilute Washing Solution 1 + 19; e.g. 10 ml Washing Solution + 190 ml fresh and germ free destilled water. The diluted buffer is stable for 5 days at room temperature. Crystals in the concentrate disappear by warming up to 37 °C in a water bath.

6.3. TMB Substrate Solution
The reagent is ready to use and has to be stored at 2±8 °C, away from the light. The solution should be colourless or could have a slight blue tinge. If the substrate turns into blue, it may have become contaminated and should be thrown away.

7. SPECIMEN COLLECTION AND PREPARATION
Use human serum or plasma (heparin) samples with this assay. If the assay is performed within 5 days after sample collection, the specimens should be kept at 2±8 °C; otherwise they should be aliquoted and stored deep-frozen (-70...-20 °C). If samples are stored frozen, mix thawed samples well before testing. Avoid repeated freezing and thawing.
Heat inactivation of samples is not recommended.

7.1. Sample Dilution
Before assaying, all samples should be diluted 1+100 with IgG Sample Diluent. Dispense 10 μl sample and 1 ml IgG Sample Diluent into tubes to obtain a 1+100 dilution and thoroughly mix with a Vortex.

8. ASSAY PROCEDURE
8.1. Test Preparation
Please read the test protocol carefully before performing the assay. Result reliability depends on strict adherence to the test protocol as described. If performing the test on ELISA automatic systems we recommend increasing the washing steps from three to five and the volume of Washing Solution from 300 μl to 350 μl to avoid washing effects. Pay attention to chapter 12. Prior to commencing the assay, the distribution and identification plan for all specimens and standards/controls should be carefully established on the result sheet supplied in the kit. Select the required number of microtitre strips or wells and insert them into the holder.

Please allocate at least:
1 well (e.g. A1) for the Substrate Blank,
1 well (e.g. B1) for the Negative Control,
2 wells (e.g. C1+D1) for the Cut-off Control and
1 well (e.g. E1) for the Positive Control.
It is recommended to determine standards/controls and patient samples in duplicate. Perform all assay steps in the order given and without any appreciable delays between the steps. A clean, disposable tip should be used for dispensing each standard/control and sample.

Adjust the incubator to 37 ± 1 °C.

1. Dispense 100 µl standards/controls and diluted samples into their respective wells. Leave well A1 for the Substrate Blank.
2. Cover wells with the foil supplied in the kit.
3. Incubate for 1 hour ± 5 min at 37 ± 1 °C.
4. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well three times with 300 µl of Washing Solution. Avoid overflows from the reaction wells. The soak time between each wash cycle should be > 5 sec. At the end carefully remove remaining fluid by tapping strips on tissue paper prior to the next step.
   Note: Washing is critical! Insufficient washing results in poor precision and falsely elevated absorbance values.
5. Dispense 100 µl Leptospira anti-IgG Conjugate into all wells except for the Substrate Blank well (e.g. A1). Cover with foil.
6. Incubate for 30 min at room temperature. Do not expose to direct sunlight.
7. Repeat step 4.
8. Dispense 100 µl TMB Substrate Solution into all wells.
9. Incubate for exactly 15 min at room temperature (20...26 °C) in the dark.
10. Dispense 100 µl Stop Solution into all wells in the same order and at the same rate as for the TMB Substrate.
   Any blue colour developed during the incubation turns into yellow.
11. Measure the absorbance of the specimens at 450/620 nm within 30 min after addition of the Stop Solution.

8.2. Measurement
Adjust the ELISA Microwell Plate Reader to zero using the Substrate Blank in well A1.
If - due to technical reasons - the ELISA reader cannot be adjusted to zero using the Substrate Blank in well A1, subtract the absorbance value of well A1 from all other absorbance values measured in order to obtain reliable results!
Measure the absorbance of all wells at 450 nm and record the absorbance values for each standard/control and patient sample in the distribution and identification plan.
Dual wavelength reading using 620 nm as reference wavelength is recommended.
Where applicable calculate the mean absorbance values of all duplicates.

9. RESULTS
9.1. Run Validation Criteria
In order for an assay to be considered valid, the following criteria must be met:

- **Substrate Blank** in A1: Absorbance value < 0.100
- **Negative Control** in B1: Absorbance value < 0.200 and < Cut-off
- **Cut-off Control** in C1 and D1: Absorbance value 0.150 - 1.300
- **Positive Control** in E1: Absorbance value > Cut-off

If these criteria are not met, the test is not valid and must be repeated.

9.2. Calculation of Results
The Cut-off is the mean absorbance value of the Cut-off Control determinations.
Example: Absorbance value Cut-off Control 0.44 + absorbance value Cut-off control 0.42 = 0.86 / 2 = 0.43
Cut-off = 0.43

9.2.1. Results in Units [NTU]
\[
\text{Patient (mean) absorbance value x } 10 \quad \frac{\text{Cut-off}}{0.43} = \text{[NoveTec Units = NTU]}
\]

Example: \[
\frac{1.591 \times 10}{0.43} = 37 \text{ NTU (Units)}
\]
9.3. Interpretation of Results

<table>
<thead>
<tr>
<th>Cut-off</th>
<th>Antibodies against the pathogen are present. There has been a contact with the antigen (pathogen resp. vaccine).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>&gt; 11 NTU</td>
</tr>
<tr>
<td>Equivocal</td>
<td>9 – 11 NTU. Antibodies against the pathogen could not be detected clearly. It is recommended to repeat the test with a fresh sample in 2 to 4 weeks. If the result is equivocal again the sample is judged as negative.</td>
</tr>
<tr>
<td>Negative</td>
<td>&lt; 9 NTU. The sample contains no antibodies against the pathogen. A previous contact with the antigen (pathogen resp. vaccine) is unlikely.</td>
</tr>
</tbody>
</table>

Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data. In immunocompromised patients and newborns serological data only have restricted value.

10. SPECIFIC PERFORMANCE CHARACTERISTICS

10.1. Precision

<table>
<thead>
<tr>
<th>Intraassay</th>
<th>n</th>
<th>Mean (OD)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample #1</td>
<td>23</td>
<td>0.437</td>
<td>3.2</td>
</tr>
<tr>
<td>Sample #2</td>
<td>24</td>
<td>0.394</td>
<td>2.4</td>
</tr>
<tr>
<td>Sample #3</td>
<td>24</td>
<td>0.544</td>
<td>2.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interassay</th>
<th>n</th>
<th>Mean (NTU)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample #1</td>
<td>12</td>
<td>21.97</td>
<td>8.2</td>
</tr>
<tr>
<td>Sample #2</td>
<td>12</td>
<td>13.10</td>
<td>3.5</td>
</tr>
</tbody>
</table>

10.2. Diagnostic Specificity

The diagnostic specificity is defined as the probability of the assay of scoring negative in the absence of the specific analyte. It is 97.4 %.

10.3. Diagnostic Sensitivity

The diagnostic sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is 98 %.

10.4. Interferences

Interferences with hemolytic, lipemic or icteric specimen are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.5 mg/ml bilirubin.

10.5. Cross Reactivity

It cannot be excluded that monoclonal B-cell activation induced by Epstein-Barr virus (EBV) or the presence of Rheumatoid Factors may result in false-positive Leptospirosis IgG antibody results.

Note: The results refer to the groups of samples investigated; these are not guaranteed specifications.

11. LIMITATIONS OF THE PROCEDURE

Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values.

12. PRECAUTIONS AND WARNINGS

- In compliance with article 1 paragraph 2b European directive 98/79/EC the use of the in vitro diagnostic medical devices is intended by the manufacturer to secure suitability, performances and safety of the product. Therefore the test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The use of the testkits with analyzers and similar equipment has to be validated. Any change in design, composition and test procedure as well as for any use in combination with other products not approved by the manufacturer is not authorized; the user himself is responsible for such changes. The manufacturer is not liable for false results and incidents for these reasons. The manufacturer is not liable for any results by visual analysis of the patient samples.
- Only for in-vitro diagnostic use.
- All materials should be regarded and handled as potentially infectious.
- All components of human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive.
- Do not interchange reagents or strips of different production lots.
- No reagents of other manufacturers should be used along with reagents of this test kit.
- Do not use reagents after expiry date stated on the label.
- Use only clean pipette tips, dispensers, and lab ware.
- Do not interchange screw caps of reagent vials to avoid cross-contamination.
- Close reagent vials tightly immediately after use to avoid evaporation and microbial contamination.
• After first opening and subsequent storage check conjugate and standard/control vials for microbial contamination prior to further use.
• To avoid cross-contamination and falsely elevated results pipette patient samples and dispense reagents without splashing accurately to the bottom of wells.
• The ELISA is only designed for qualified personnel who are familiar with good laboratory practice.
• The concentrations of the hazardous materials mentioned in point 4.1. are very low. Therefore there is hardly any toxicological risk. Nevertheless rinse with plenty of water upon contact with eyes, skin or mucous membranes and consult a doctor in case of irritations. All solutions should be handled with adequate care.

12.1. Disposal Considerations
Residues of chemicals and preparations are generally considered as hazardous waste. The disposal of this kind of waste is regulated through national and regional laws and regulations. Contact your local authorities or waste management companies which will give advice on how to dispose hazardous waste.

13. ORDERING INFORMATION
Prod. No.:       LEPG0660       Leptospira IgG-ELISA (96 Determinations)